Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM1SCU5)

• Drug Name: Nalorphine Drug Info
• Synonyms: Nalorphine; Allorphine; Nalorphinium; Antorphin; Antorfin; Anthorphine; Nalorphin; Antorphine; N-Allylnormorphine; Anarcon; Nalorfina; Norfin; Nallin; 62-67-9; Acetorfin [Czech]; Nalorfina [DCIT]; NANM; Normorphine, N-allyl-; Nalorphine [INN:BAN]; Nalorphinum [INN-Latin]; UNII-U59WB2WRY2; N-Allyl-N-desmethylmorphine; HSDB 3278; EINECS 200-546-1; U59WB2WRY2; Acetorfin; CHEBI:7458; Morphinan-3,6-diol, 7,8-didehydro-4,5-epoxy-17-(2-propenyl)-, (5alpha,6alpha)-; N-Allyl-7,8-dehydro-4,5-epoxy-3,6-dihydroxymorphinan; DEA No. 9400

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 5284595
  ChEBI ID: CHEBI:7458
  CAS Number: CAS 62-67-9
  TTD Drug ID: DM1SCU5

Molecule-Related Drug Atlas

Drug(s) Targeting Opioid receptor kappa (OPRK1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Nalbuphine	DMOSQGU	Pain	MG30-MG3Z	Approved	[4]
Nalfurafine hcl	DMA9DHW	Uremic pruritus	EC90.10	Approved	[5]
CHLOROXINE	DMFZBMQ	Erythema	ME64.0	Approved	[6]
Difelikefalin	DMHZBEO	Pruritus	EC90	Approved	[7]
Dezocine	DMJDB0Y	Pain	MG30-MG3Z	Approved	[8]
Asimadoline	DMND3AB	Diarrhea-predominant irritable bowel syndrome	DD91.01	Phase 3	[9]
JNJ 67953964	DMJ8Y5N	Major depressive disorder	6A70.3	Phase 3	[10]
PHN-131	DM1SV8I	Pain	MG30-MG3Z	Phase 2/3	[11]
CR-845	DMJYTUQ	Pain	MG30-MG3Z	Phase 2/3	[12]
Carfentanil	DM7ADGX	N. A.	N. A.	Phase 2	[13]

Drug(s) Affected By Prolactin (PRL)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[14]
Ranitidine	DM0GUSX	Gastric ulcer	DA60	Approved	[15]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[16]
Citalopram	DM2G9AE	Acute coronary syndrome	BA41	Approved	[17]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[18]
Thioridazine	DM35M8J	Schizophrenia	6A20	Approved	[19]
Naloxone	DM3FXMA	Narcotic depression	6A7Z	Approved	[20]
Aripiprazole	DM3NUMH	Bipolar I disorder		Approved	[21]
Fluoxetine	DM3PD2C	Bipolar depression		Approved	[22]
Penicillamine	DM40EF6	Cystinuria	5C60.2	Approved	[23]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Opioid receptor kappa (OPRK1)	TTQW87Y	OPRK_HUMAN	Agonist	[2]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Prolactin (PRL)	OTWFQGX7	PRL_HUMAN	Gene/Protein Processing	[3]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1629).
• [2] Apparent efficacy of kappa-opioid receptor ligands on serum prolactin levels in rhesus monkeys. Eur J Pharmacol. 1999 Nov 3;383(3):305-9.
• [3] Changes in nalorphine-induced hyperprolactinaemia after bromocriptine or sulpiride administration. Eur J Clin Pharmacol. 1982;22(4):375-6. doi: 10.1007/BF00548408.
• [4] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [5] Drug design and synthesis of a novel kappa opioid receptor agonist with an oxabicyclo[2.2.2]octane skeleton and its pharmacology. Bioorg Med Chem Lett. 2010 Jan 1;20(1):121-4.
• [6] In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6.
• [7] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [8] Pharmacological profiles of opioid ligands at kappa opioid receptors. BMC Pharmacol. 2006 Jan 25;6:3.
• [9] Emerging drugs for irritable bowel syndrome. Expert Opin Emerg Drugs. 2006 May;11(2):293-313.
• [10] Kappa Opioid Receptor Antagonists as Potential Therapeutics for Mood and Substance Use Disorders. Handb Exp Pharmacol. 2022;271:473-491.
• [11] Nalbuphine: an autoradiographic opioid receptor binding profile in the central nervous system of an agonist/antagonist analgesic. J Pharmacol Exp Ther. 1988 Jan;244(1):391-402.
• [12] Peptide Kappa Opioid Receptor Ligands: Potential for Drug Development. AAPS J. 2009 June; 11(2): 312-322.
• [13] Wax PM, Becker CE, Curry SC: Unexpected gas casualties in Moscow: a medical toxicology perspective. Ann Emerg Med. 2003 May;41(5):700-5.
• [14] Verapamil-induced hyperprolactinemia complicated by a pituitary incidentaloma. Ann Pharmacother. 1995 Oct;29(10):999-1001. doi: 10.1177/106002809502901009.
• [15] [Impotence and gynecomastia secondary to hyperprolactinemia induced by ranitidine]. Therapie. 1994 Jul-Aug;49(4):361-2.
• [16] Differential effects of estrogen receptor antagonists on pituitary lactotroph proliferation and prolactin release. Mol Cell Endocrinol. 2005 Jul 15;239(1-2):27-36. doi: 10.1016/j.mce.2005.04.008.
• [17] Cholinergic modulation of the cerebral metabolic response to citalopram in Alzheimer's disease. Brain. 2009 Feb;132(Pt 2):392-401. doi: 10.1093/brain/awn326. Epub 2009 Jan 19.
• [18] The contribution of methotrexate exposure and host factors on transcriptional variance in human liver. Toxicol Sci. 2007 Jun;97(2):582-94.
• [19] The effect of thioridazine on prolactinoma growth in a schizophrenic man: case report. Gen Hosp Psychiatry. 1985 Oct;7(4):364-6. doi: 10.1016/0163-8343(85)90053-2.
• [20] Influence of naloxone on muscle sympathetic nerve activity, systemic and calf haemodynamics and ambulatory blood pressure after exercise in mild essential hypertension. J Hypertens. 1995 Apr;13(4):447-61.
• [21] The efficacy, safety, and tolerability of aripiprazole for the treatment of schizoaffective disorder: results from a pooled analysis of a sub-population of subjects from two randomized, double-blind, placebo-controlled, pivotal trials. J Affect Disord. 2009 May;115(1-2):18-26. doi: 10.1016/j.jad.2008.12.017. Epub 2009 Feb 23.
• [22] Serum prolactin levels among outpatients with major depressive disorder during the acute phase of treatment with fluoxetine. J Clin Psychiatry. 2006 Jun;67(6):952-7. doi: 10.4088/jcp.v67n0612.
• [23] Massive breast enlargement in a patient receiving D-penicillamine for systemic sclerosis. J Rheumatol. 1985 Oct;12(5):990-1.